Table 2.
In vitro enzyme‐linked immunospot assay before the initiation of therapy and after 2 cycles of treatment in the HLA‐A2402 matched group
| Number | CTL response (RNF43/TOMM34) | ||
|---|---|---|---|
| Before the initiation of therapy | After 2 cycles of therapy | Assessment | |
| 1 | +/+ | NA/NA | Not assessed |
| 2 | −/− | −/NA | Not assessed |
| 3 | −/+ | −/+ | Positive |
| 4 | −/− | +/− | Positive |
| 5 | −/+ | −/− | Negative |
| 6 | −/− | NA/NA | Not assessed |
| 7 | +/− | +/− | Positive |
| 8 | −/− | +/− | Positive |
| 9 | −/− | −/+ | Positive |
| 10 | −/− | −/− | Negative |
| 11 | −/− | +/− | Positive |
| 12 | −/− | −/− | Negative |
| 13 | +/− | +/− | Positive |
| 14 | +/− | −/+ | Positive |
| 15 | −/− | −/− | Negative |
| 16 | −/− | +/− | Positive |
| 17 | +/NA | +/+ | Positive |
| 18 | −/NA | −/− | Negative |
| 19 | −/− | −/− | Negative |
| 20 | −/− | −/− | Negative |
| 21 | −/− | −/− | Negative |
| 22 | +/+ | −/NA | Not assessed |
| 23 | −/− | +/NA | Positive |
| 24 | −/NA | −/− | Negative |
| 25 | −/− | −/+ | Positive |
| 26 | +/− | +/− | Positive |
| 27 | +/− | −/+ | Positive |
| 28 | −/− | −/NA | Not assessed |
NA, not available.